Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
CNY 10.93
(1.3%)
CNY 10.93
(1.3%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.48 Billion CNY | -2.64% |
| 2022 | 3.58 Billion CNY | -0.26% |
| 2021 | 3.59 Billion CNY | 10.42% |
| 2020 | 3.25 Billion CNY | -13.01% |
| 2019 | 3.74 Billion CNY | -18.62% |
| 2018 | 4.59 Billion CNY | 7.44% |
| 2017 | 4.27 Billion CNY | 25.17% |
| 2016 | 3.41 Billion CNY | 136.26% |
| 2015 | 1.44 Billion CNY | 132.89% |
| 2014 | 621.24 Million CNY | 31.92% |
| 2013 | 470.91 Million CNY | 42.17% |
| 2012 | 331.23 Million CNY | 84.88% |
| 2011 | 179.16 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.44 Billion CNY | -1.4% |
| 2024 Q3 | 3.56 Billion CNY | 1.49% |
| 2024 Q2 | 3.51 Billion CNY | 2.05% |
| 2023 Q3 | 3.56 Billion CNY | 1.16% |
| 2023 FY | 3.48 Billion CNY | -2.64% |
| 2023 Q1 | 3.47 Billion CNY | -3.09% |
| 2023 Q2 | 3.52 Billion CNY | 1.38% |
| 2023 Q4 | 3.48 Billion CNY | -2.04% |
| 2022 Q4 | 3.58 Billion CNY | -1.45% |
| 2022 FY | 3.58 Billion CNY | -0.26% |
| 2022 Q2 | 3.61 Billion CNY | 2.56% |
| 2022 Q1 | 3.52 Billion CNY | -1.81% |
| 2022 Q3 | 3.63 Billion CNY | 0.5% |
| 2021 Q3 | 3.6 Billion CNY | -3.62% |
| 2021 Q2 | 3.74 Billion CNY | 0.41% |
| 2021 Q1 | 3.73 Billion CNY | 14.63% |
| 2021 FY | 3.59 Billion CNY | 10.42% |
| 2021 Q4 | 3.59 Billion CNY | -0.46% |
| 2020 FY | 3.25 Billion CNY | -13.01% |
| 2020 Q4 | 3.25 Billion CNY | -3.1% |
| 2020 Q3 | 3.35 Billion CNY | -5.02% |
| 2020 Q2 | 3.53 Billion CNY | -0.66% |
| 2020 Q1 | 3.55 Billion CNY | -4.86% |
| 2019 Q2 | 4.64 Billion CNY | -1.14% |
| 2019 Q1 | 4.69 Billion CNY | 2.21% |
| 2019 FY | 3.74 Billion CNY | -18.62% |
| 2019 Q4 | 3.74 Billion CNY | -16.79% |
| 2019 Q3 | 4.49 Billion CNY | -3.21% |
| 2018 Q2 | 4.51 Billion CNY | 35.02% |
| 2018 Q1 | 3.34 Billion CNY | -21.88% |
| 2018 FY | 4.59 Billion CNY | 7.44% |
| 2018 Q4 | 4.59 Billion CNY | 3.49% |
| 2018 Q3 | 4.44 Billion CNY | -1.57% |
| 2017 FY | 4.27 Billion CNY | 25.17% |
| 2017 Q1 | 2.59 Billion CNY | -24.21% |
| 2017 Q4 | 4.27 Billion CNY | 44.62% |
| 2017 Q3 | 2.95 Billion CNY | 9.21% |
| 2017 Q2 | 2.7 Billion CNY | 4.56% |
| 2016 Q2 | 1.96 Billion CNY | 16.65% |
| 2016 Q4 | 3.41 Billion CNY | 61.03% |
| 2016 Q3 | 2.12 Billion CNY | 7.99% |
| 2016 Q1 | 1.68 Billion CNY | 16.47% |
| 2016 FY | 3.41 Billion CNY | 136.26% |
| 2015 Q2 | 1.33 Billion CNY | 121.23% |
| 2015 Q3 | 1.39 Billion CNY | 4.51% |
| 2015 Q1 | 603.05 Million CNY | -2.93% |
| 2015 FY | 1.44 Billion CNY | 132.89% |
| 2015 Q4 | 1.44 Billion CNY | 3.77% |
| 2014 Q4 | 621.24 Million CNY | 4.75% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 FY | 621.24 Million CNY | 31.92% |
| 2014 Q3 | 593.09 Million CNY | 0.0% |
| 2013 FY | 470.91 Million CNY | 42.17% |
| 2012 FY | 331.23 Million CNY | 84.88% |
| 2011 FY | 179.16 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 17.93 Billion CNY | 80.55% |
| Hangzhou Tigermed Consulting Co., Ltd. | 29.69 Billion CNY | 88.251% |
| Dirui Industrial Co.,Ltd. | 3.32 Billion CNY | -5.072% |
| Beijing Strong Biotechnologies, Inc. | 5.17 Billion CNY | 32.586% |
| Maccura Biotechnology Co.Ltd | 8.11 Billion CNY | 57.026% |
| Guangzhou Wondfo Biotech Co.,Ltd | 5.77 Billion CNY | 39.547% |
| Guangdong Hybribio Biotech Co.,Ltd. | 5.72 Billion CNY | 39.062% |
| BGI Genomics Co., Ltd. | 13.61 Billion CNY | 74.369% |
| Amoy Diagnostics Co., Ltd. | 1.93 Billion CNY | -80.331% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 2.98 Billion CNY | -16.818% |